
To summarise contemporary evidence on the impact of lifestyle interventions and mental health management on arrhythmias in patients with heart failure (HF), and to highlight emerging therapeutic opportunities. Lifestyle modification targets shared risk factors in both arrhythmias and HF. In atrial fibrillation (AF), weight loss, exercise, alcohol reduction, and risk factor management reduce arrhythmia burden and improve arrhythmia-related symptoms and quality of life. Similarly, in both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), exercise training improves functional capacity and quality of life, whilst dietary interventions and weight loss are particularly beneficial in HFpEF. Mental health disorders represent novel targets for intervention for arrhythmias in HF; these conditions are common in arrhythmia and HF patients and associated with poorer outcomes, but early data suggests that mental health interventions do not reduce arrhythmia burden or cardiovascular outcomes despite improving overall psychological well-being and quality of life. Lifestyle intervention to improve physical health is central to HF and arrhythmia care and established as a central pillar of management. Mental health represents an important but under-recognised target which requires urgent further investigation.
Purpose of Review: Cancer survivors have an elevated risk for developing heart failure due to prior chemotherapy, radiation therapy, and other overlapping co-morbid conditions. With the advancement in cancer treatment, there is an increasing number of survivors who are at an even higher risk of developing heart failure. There is a growing need for heart failure specific risk prediction models in this population to facilitate early diagnosis and timely management. This review aims to summarize most recent findings on heart failure risk prediction among patients with history of cancer. Recent findings: Current risk prediction models focus on heart failure risk at the time of cancer treatment and shortly thereafter. There is limited data on heart failure risk among long term survivors. Central Figure: Approach in determining heart failure risk before, during, and, after cancer treatment
To summarise the contemporary pharmacological management of atrial fibrillation (AF) in heart failure (HF), focusing on rate and rhythm control and upstream therapies across the ejection fraction spectrum. Rate control remains a cornerstone of AF management, particularly in permanent AF or haemodynamically fragile patients, with beta-blockers, digoxin, and non-dihydropyridine calcium channel blockers selected according to ejection fraction phenotype. Concurrently, increasing evidence supports early rhythm-control strategies because of their prognostic benefits in HF populations, with current guidelines reinforcing a left ventricular ejection fraction (LVEF)-guided approach to antiarrhythmic drug selection. Beyond conventional drugs, HF guideline-directed medical therapy (GDMT) is emerging as an important upstream pharmacological strategy for modulation of the arrhythmogenic substrate. AF management in HF requires an integrated, phenotype-oriented approach combining symptom control, thromboembolic prevention, and optimisation of GDMT. LVEF remains a key determinant of pharmacological safety and therapeutic selection, whereas haemodynamic status primarily guides acute management decisions.
Atrial fibrillation (AF) and heart failure (HF) frequently coexist and represent a major source of cardiovascular morbidity and mortality. This review summarizes current evidence on sex-specific differences in epidemiology, pathophysiology, clinical presentation, prognosis, and treatment in women with AF and HF. Emerging evidence indicates that women with AF and HF constitute a distinct clinical and biological phenotype. Women typically develop AF at older age, more commonly present with hypertension and HF with preserved ejection fraction (HFpEF), and report greater symptom burden and impaired quality of life. Sex-specific mechanisms including hormonal influences, atrial fibrosis, endothelial dysfunction, inflammation, autonomic dysregulation, and microvascular disease contribute to these differences. Population studies further demonstrate sex-related disparities in HF development and outcomes across AF subtypes. Despite increasing awareness, women remain underrepresented in clinical trials and are less likely to receive rhythm-control strategies, catheter ablation, or device therapy. Recognition of the “female fingerprint” in AF and HF is essential for individualized risk stratification and the advancement of precision cardiovascular medicine.
Heart failure with preserved ejection fraction and atrial fibrillation frequently coexist and are linked by shared mechanisms including atrial myopathy, elevated filling pressures, fibrosis, and adverse hemodynamic interactions. The combination of both diseases worsens patient outcomes, and catheter ablation has emerged as a potentially important treatment strategy in this population. This review aims to summarize and highlight the current evidence on ablation in patients with atrial fibrillation and HFpEF. When examining outcomes of mortality, hospitalization, hemodynamics, and recurrence, ablation appears to be superior to medical treatment with some mixed results. However, no large trials have been conducted on the topic, and no clear guidelines for ablation in HFpEF patients exist. Ablation is promising but not yet definitive for patients with atrial fibrillation and HFpEF. Ongoing trials, including CASTLE-HFpEF should clarify the gaps including patient selection, procedural strategy, and outcome benefit.